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Objectives for this talk 
• Brief discussion of pathogenesis of type 2 
diabetes 
• Treatment rationale and targets 
• Updated approaches to glycemic control, 
BP and lipids in type 2 diabetes 
• New on the horizon 
What goes wrong in type 2 
diabetes?  
• Insulin resistance 
• Impaired (not absent) ability to 
secrete insulin 
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Bottom line: Type 2 diabetes is a progressive disorder 
Need to consider therapeutic implications of this.  
How do we prevent diabetes or stop the progression of 
early type 2 diabetes? 
• Patients with A1c 5.7–6.4% should be targeted to weight loss of 7% and at least 
moderate activity (e.g. walking) for at least 150 min/week. 
– Lifestyle change effective as long as 20 years in Da Qing study 
– 7% weigh loss based on US prevention trial (DPP2) 
• Metformin therapy for prevention of type 2 diabetes may be considered in those 
with IGT , IFG, or an A1C 5.7–6.4% 
– Metformin may be as effective as lifestyle if BMI > 35 
– Not better than placebo in older subjects (> age 60) 
• Annual monitoring for the development of diabetes 
• a-glucosidase inhibitors, orlistat, thiazolidinediones (TZDs), glargine insulin have 
been shown to decrease incident diabetes to various degrees 
• TZDs may prevent the onset of diabetes in subjects at risk and prevent 
worsening of early diabetes 
– But associated with worrisome adverse effects  
– Effects over long term od concern 
• Incretin therapy increases islet mass in rodents 
• GRADE study ongoing 
Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537 
DREAM Trial. Lancet 2006;368:1096–1105 
Diabetes Prevention Program. NEJM 2002;346:393 
Finnish Diabetes Prevention Study. NEJM 2001;344:1343 
STOPNIDDM trial. Lancet 2002; 359:20727 
SHAI et al: NEJM 2008;359:229-41. 
NEJM 2012 Jul 26;367(4):319-28 
ADA Treatment Goals for Glycemic Control 
Preprandial capillary 
plasma glucose  
HgbA1c (%) 
70-130 mg/100 ml 
< 7.0% (normal 4.0 -6.0) 
American Diabetes Association: Standards of Care (Diabetes Care 
37, Suppl. 1, Jan. 2014) Online www.diabetes.org/ 
Peak postprandial 
plasma glucose 
< 180 mg/100 ml 
Selected Individuals As close to normal as possible 
without significant hypoglycemia 
Severe lows, limited life 
expectancy, co-morbidity, 
children, long hx DM with 
minimal complications, 
hypoglycemic unawareness 
Less stringent (e.g. 
HbA1c < 8.0) 
Beigi et. al. Individualizing glycemic targets in type 2 
diabetes mellitus: implications of recent clinical trials. 
Ann Intern Med 2011;154: 554–559 
Some important diabetes treatment 
trials 
 
ACCORD           ADVANCE VADT 
# subjects 10,251 11,140 1,791 
Average age 62 66 60 
A1c control 6.4 vs 7.5 % 6.4 vs 7.0 % 6.9 vs 8.4 % 
Primary results No decrease in 
cardiovascular events. 
Increased cardiovascular 
mortality with intensive 
Rx 
No decrease in 
cardiovascular risk 
Reduced risk of 
nephropathy 
 
No decrease in 
cardiovascular risk 
 
Glycemic control and macrovascular disease 
in ACCORD, ADVANCE, and VADT 
 Large randomized trials directed at the effect of glycemic control on 
cardiovascular risk in type 2 diabetes in participants at high risk for 
vascular events. 
Data from DCCT/EDIC and UKPDS 
• DCCT  
– Nine years after DCCT, 
incidence of CV events 
was reduced 57% in 
former intensive patients 
– Younger age at onset (13-
39) with no known CVD 
 
• UKPDS 
– 10 years after UKPDS, 
follow-up showed at 15% 
decrease in MI in intense 
treatment group initially on 
sulfonylurea or insulin; and 
33% in more obese treated 
initially with metformin.  
– Mortality also reduced 13 
and 27% respectively  
 
Nathan DM, et. al. NEJM 353:2643, 2005 
Holman RR, et. al. NEJM 359, 1577, 2008 

Implications of major Rx trials 
• Target of 7.0 % HbA1c still considered valid 
• More aggressive treatment may need to be implemented 
early with cautious approach with more advanced 
diabetes and cardiovascular disease 
• Overly persistent efforts to lower glucose in patients at 
risk for macrovascular events may not be warranted 
• Strong evidence for microvascular benefits of glucose 
control 
• Treat BP, lipids, smoking cessation, nutrition and  
lifestyle 
• Type 3 DM worsens with time. Can we prevent this? 
Drug therapy for type 2 diabetes 
Metformin 
• Near universal acceptance as initial drug 
therapy in absence of contraindication (e.g. 
renal failure, hypoxia) 
• Decrease hepatic glucose release and 
increases muscle glucose uptake 
• Beneficial effects on weight and lipids 
• Lack of hypoglycemia when used alone 
• Generic drug with long history of use 
worldwide 
Drug Actions Mechanism Advantages Disadvantages 
Sulfonylureas 
  glipizide 
  glimepiride 
  glyburide 
↑ β-cell 
insulin 
secretion 
Potassium 
channels 
Well tolerated 
Low cost 
Hypoglycemia 
Weight gain 
Low durability 
May reduce myocardial 
ischemic reconditioning 
GLP-1 
agonists 
  exenatide 
  liraglutide 
↑ insulin 
secretion 
↓ glucagon 
↓ gastric 
emptying 
↑ satiety 
Activate GLP-1 
receptors in  
β-cell, and 
nervous system  
Weight loss 
Possible ↑β-
cell 
mass/function 
Little 
hypoglycemia 
Nausea, vomiting, 
diarrhea 
Acute pancreatitis risk 
? Medullary thyroid 
tumors 
Long term safety? 
DPP-4 
inhibitors 
  sitagliptin 
  vildagliptin 
  saxagliptin 
  linagliptin 
↑ insulin 
secretion 
↓ glucagon  
Prevent GLP-1 
break-down 
↑ endogenous  
GLP-1 
Little or no 
hypoglycemia 
Weight neutral 
Urticaria, angioedema 
Pancreatitis 
Long term safety? 
Insulin Well known Well Known Effective, 
“natural” 
Hypoglycemia, Weight 
gain,  may need multiple 
injections and large dose 
Drugs for type 2 diabetes beyond Metformin 
Drug Actions Mechanism Advantages Disadvantages 
Canagliflozin 
Dapaglifloxin 
Increase 
urine 
glucose 
excretion 
Inhibits hSGLT2 
(sodium/glucose 
cotransporter) 
in renal tubules 
Hypoglycemia 
very unusual 
Familial renal 
glycosuria is a 
benign disease 
UTIs, vulvovaginitis, 
balanitis: mostly mild, 
rarely limit therapy 
Osmotic diuresis 
Dehydration, 
Hypotension, 
Increased hepatic 
glucose output 
Drugs for type 2 diabetes beyond Metformin (continued) 
Pending are postmarketing studies: a 
cardiovascular outcomes trial; an 
enhanced pharmacovigilance program to 
monitor for malignancies, pancreatitis, 
hypersensitivity reactions, 
photosensitivity reactions, liver 
abnormalities, and adverse pregnancy 
outcomes; a bone safety study; and two 
pediatric studies under the Pediatric 
Research Equity Act  
Drug Actions Mechanism Advantages Disadvantages 
Meglitinides 
  repaglinide 
  nateglinide 
↑ β-cell 
insulin 
secretion 
Potassium 
channels 
Action focused 
on time of 
food 
intake 
Not very effective 
Other concerns shared 
with sulfonylureas 
Thiazolidine-
diones (TZDs) 
  pioglitazone 
  rosiglitazone 
↑ Insulin 
sensitivity 
mainly in 
muscle 
Activate PPAR-γ Pioglit  ↑ HDL, 
↓ TG 
No 
hypoglycemia 
Any use is questionable 
Wt gain, edema, CHF,  
↑ LDL, bone fractures, 
bladder CA 
Rosiglit ↑ CV events 
α-glucosidase 
Inhibitors 
  acarbose 
  miglitol 
↓ 
intestinal 
glucose 
absorption 
Inhibit α-
glucosidase 
Nonsystemic 
No 
hypoglycemia 
Not very effective 
GI gas, diarrhea 
colesevelam Unclear Bile acid 
sequestrant 
No 
hypoglycemia 
Constipation, ↑ TGS 
↓ absorption of meds 
bromocriptine ↑ Insulin 
sensitivity  
Hypothalamic 
dopaminergic 
effect 
No 
hypoglycemia 
Dizziness, syncope, 
nausea, fatigue, rhinitis, 
Long term safety? 
Drugs for type 2 diabetes  beyond metformin (less often used) 
Initial Pharmacologic treatment 
Metformin 
Goal achieved Goal not achieved 
Another drug Add second drug 
Contraindication or 
intolerance to metformin) 
What drug ? 
Severe hyperglycemia 
Insulin 
 
Glycemia Reduction Approaches in Diabetes:  
A Comparative Effectiveness Study 
(GRADE Study) 
 
 
   To carry out an unbiased comparison of the   
    most commonly used drugs to treat  
    diabetes in metformin-treated patients. 
 
Overall Goal of GRADE study 
Screening 
Type 2 diabetes  
Treated with metformin alone 
HbA1c >6.8% at screening 
<10 years duration of diagnosed diabetes at screening 
Metformin run-in                                                                                        
Titrate metformin to 1000 (min) – 2000 (goal) mg/day 
Randomization              
n=5000 eligible subjects 
Sulfonylurea    
(glimepiride)      
n=1250 
DPP-4 inhibitor    
(sitagliptin)      
n=1250 
GLP-1 analog   
(liraglutide)      
n=1250 
Insulin    
(glargine)      
n=1250 
HbA1c 6.8-8.5% at final run-in visit             
Grade Objectives 
• Comparison of the relative effects of four commonly 
used diabetes medications with different mechanisms of 
action on durability of glycemic control (i.e. prevention of 
worsening of the diabetic state) 
– Maintenance of metabolic control, defined as time-to-primary 
failure with A1c >7.0%, confirmed, while on maximally tolerated 
doses of both metformin, up to 2000 mg/d,  and the assigned 
medication 
– Time dependent loss of insulin secretory capacity and insulin 
sensitivity 
• CVD risk factors 
• Adverse effects, tolerability and quality-of- life 
Grade Problem 
• Recruiting is difficult. We need your help! 
• Major criteria for participation 
– On Metformin alone 
– Diabetes < 10 years 
– A1c somewhere close to range required for eligibility (6.8 to 8.5) 
(Can be screened even if off a bit) 
• What can be done without interfering with a busy 
practice schedule? 
– Place brochures or poster in waiting room 
– Direct patient to brochure and/or advise to call the number listed 
– If you wish, call us yourself or have staff call 
• All participants are required (per eligibility criteria) to 
have an ongoing relationship with a primary provider. 
• We offer recognition as a research partner. 
Insulin 
• Most effective 
• “Natural” 
• Least expensive 
• Once daily for many patients 
• Less weight gain than TZD 
• Essentially no side effects apart 
from hypoglycemia 
 
• Weight gain 
• Injections 
 
Advantages Disadvantages 

Insulin regimens 
• Simple: once or twice daily 
• Complex: basal and bolus Rx using 
multiple doses 
• Choice depends on severity of 
diabetes 
JAMA 289:2254-2264, 2003 
Med Clin N Am 88, 865–895, 2004 

Basal Insulin 
Basal 
Bolus 
U-500 insulin 
• 500 units/ml (as opposed to 100 units/ml for U-100 insulin 
• There are no U-500 syringes so, e.g. 25 units drawn in a U-
100 syringe will deliver 125 units of insulin. 
• Effect begins within 30 minutes, has peak similar to U-100 
regular human insulin but has a relatively long duration of 
activity following a single dose (up to 24 hours) as 
compared with U-100 regular insulin. 
• Formulated as regular insulin but duration longer than 
regular 
• Generally used in multiple doses pre-meals and sometimes 
HS – but does not match well to meal glucose absorption 
• Can be used in pumps  
Prescribing information, Eli Lilly Co, Indianapolis, IN 
Lilly USA, LLC 2014 
Lipid lowering therapy (American Diabetes Association) 
• Lifestyle modification:  reduction of saturated fat, trans fat, and cholesterol intake; increase 
of n-3 fatty acids, viscous fiber and plant stanols/sterols; weight loss (if indicated) and 
physical activity  
• Statin therapy should be added to lifestyle, regardless of baseline lipid levels, for diabetic 
patients 
– with overt CVD 
– without CVD who are over the age of 40 years and have one or more other CVD  risk factors 
(family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria).  
• For lower-risk patients than the above statin therapy should be considered if 
– LDL cholesterol remains above 100 mg/dl  
– multiple CVD risk factors.  
• Without overt CVD, the goal is LDL cholesterol of 100 mg/dL. 
• With overt CVD, the goal is LDL cholesterol of 70 mg/dL with a high dose of a statin as an 
option.  
• If drug-treated patients do not reach the above targets on maximum tolerated statin 
therapy, a reduction in LDL cholesterol of  30–40% from baseline is an alternative goal.  
• Triglycerides:  Goals are 50 mg/dL and HDL cholesterol  40 mg/dL in men and 50 mg/dL in 
women. 
• LDL cholesterol–targeted statin therapy remains the preferred strategy.  
• Combination therapy has been shown not to provide additional benefit above statin alone. 
• Statin therapy is contraindicated in pregnancy.  
American Diabetes Association: Standards of Care (Diabetes Care 37, Suppl. 1, Jan. 2014) 
Online www.diabetes.org/ 
Yes
Age <75 y
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)
Adults age >21 y and 
a candidate for statin therapy
Yes
High-intensity statin
(Moderate-intensity statin if not 
candidate for high-intensity statin)
Yes
No
Moderate-intensity statin
No
Estimate 10-y ASCVD Risk 
with Pooled Cohort Equations*
No
Yes
 
ASCVD prevention benefit of statin 
therapy may be less clear in other groups
In selected individuals, consider additional factors 
influencing ASCVD risk‡ and potential ASCVD risk 
benefits and adverse effects, drug-drug interactions, 
and patient preferences for statin treatment
No
ASCVD Statin Benefit Groups
Heart healthy lifestyle habits are the foundation of ASCVD prevention.
In individuals not receiving cholesterol-lowering drug therapy, recalculate estimated 
10-y ASCVD risk every 4-6 y in individuals aged 40-75 y without clinical ASCVD or 
diabetes and with LDL–C 70-189 mg/dL.
Yes
Estimated 10-y ASCVD risk ≥7.5%*
High-intensity statin
Age >75 y OR if not candidate for 
high-intensity statin
Moderate-intensity statin
Yes
Yes
Clinical 
ASCVD
LDL–C ≥190 
mg/dL
Diabetes
Type 1 or 2
Age 40-75 y
≥7.5% estimated
10-y ASCVD risk
and age 40-75 y
Moderate-to-high intensity statin
Definitions of High- and 
Moderate-Intensity Statin Therapy
(See Table 5)
High
Daily dose lowers 
LDL–C by appox. 
≥50%
Moderate
Daily dose lowers 
LDL–C by appox. 
30% to <50%
Higher intensity = 
atorvastatin 40–80 mg 
Moderate intensity = 
atorvastatin 10 mg, 
pravastatin 40 mg, or 
simvastatin 20–40 mg  
A conservative estimate of 
adverse events includes 
excess cases of incident 
diabetes, myopathy, and 
hemorrhagic stroke.  
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce 
Atherosclerotic Cardiovascular Risk in Adults, Circulation, Nov. 12, 2013 
BP goals (American Diabetes Association) 
• People with diabetes and hypertension should be 
treated to a systolic blood pressure (SBP) goal of 140 
mmHg.  
• Lower systolic targets, such as 130 mmHg, may be 
appropriate for certain individuals, such as younger 
patients, if it can be achieved without undue 
treatment burden. 
• Patients with diabetes should be treated to a 
diastolic blood pressure (DBP) 80 mmHg. 
American Diabetes Association: Standards of Care (Diabetes Care 37, 
Suppl. 1, Jan. 2014) Online www.diabetes.org/ 
HOPE study and M ICRO-HOPE substudy. Lancet 2000;355: 253–259 
ADVANCE Collaborative Group. N Engl J Med 2008;358:2560–2572  
BP treatment (American Diabetes Association) 
• Remember lifestyle treatment 
• RAS inhibitors have advantages 
• Diuretics are effective and often added to ACE/ARB 
therapy 
– RAS inhibitors and diuretics are effective in reducing CV events 
in type 2 diabetes 
– RAS inhibitors protect against microvascular complications 
• Often need multi-drug therapy, usually include diuretic if 
triple drug therapy 
• If Rx not effective, consider a secondary etiology of 
hypertension 
• Avoid ACE and ARBs and diuretics in pregnancy   
American Diabetes Association: Standards of Care (Diabetes Care 37, Suppl. 1, Jan. 2014) 
Online www.diabetes.org/ 
A few new ideas 
Inhibition of PCSK9: A new way to lower cholesterol 
• PCSK9 (proprotein convertase subtilisin/kexin type 9) binds 
to LDL receptors leading to their degradation. 
– Mutations resulting in lower levels of the circulating protein 
were associated with reduced LDL and CAD risk 
– PCSK9  is a target of LDL-lowering therapies 
• Inhibit by infusion of an RNA interference drug (ALN-PCS) 
or by antibody administration 
– ALN-PCS is delivered using a lipid nanoparticle and inhibits 
synthesis of PCSK9  
• Highest ALN-PCS dose resulted in average LDL  reduction of 
40% relative to placebo (P<0.0001) 
• Still needs larger study – mainly proof of concept at his 
point  
Fitzgerald et. al. Lancet 383: 60-68, 2014 
PCSK9 pathway and RNA interference synthesis-inhibitor approach PCSK9 has a role in both  
intracellular and extracellular degradation of the LDL receptor (LDLR). PCSK9 synthesis inhibitors 
such as ALN-PCS inhibit PCSK9 synthesis (A) and therefore both intracellular and extracellular     
functions, whereas PCSK9 blockers (such as anti-PCSK9 antibodies) inhibit only extracellular 
function (B). mRNA=messenger RNA. 
Fitzgerald et. al. Lancet 383: 60-68, 2014 
Medtronic i-port 
New insulins 
• U-300 or U-?? Insulins. These will probably 
need to be administered in pen form to avoid 
dosing problems 
• New long acting insulins 
• Super short acting insulin 
END 
Thanks for your attention 
Help us make the GRADE 
